2197 related articles for article (PubMed ID: 16112192)
1. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
2. Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells.
Ahmed N; Laverick L; Sammons J; Zhang H; Maslin DJ; Hassan HT
Anticancer Res; 2001; 21(5):3519-23. PubMed ID: 11848518
[TBL] [Abstract][Full Text] [Related]
3. Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy.
Hassan HT
Leuk Res; 2004 Jul; 28(7):667-71. PubMed ID: 15158086
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia.
Suárez L; Vidriales B; García-Laraña J; López A; Martínez R; Martín-Reina V; Tormo M; González-San Miguel JD; Lavilla E; García-Boyero R; Orfao A; San Miguel JF;
Haematologica; 2001 Dec; 86(12):1287-95. PubMed ID: 11726321
[TBL] [Abstract][Full Text] [Related]
5. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
6. Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells.
Suárez L; Vidriales MB; Moreno MJ; López A; García-Laraña J; Pérez-López C; Tormo M; Lavilla E; López-Berges MC; de Santiago M; San Miguel JF; Orfao A;
Haematologica; 2005 Jan; 90(1):54-9. PubMed ID: 15642669
[TBL] [Abstract][Full Text] [Related]
7. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
[TBL] [Abstract][Full Text] [Related]
8. Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin.
Morris KL; Adams JA; Liu Yin JA
Leuk Res; 2009 Aug; 33(8):1096-9. PubMed ID: 19268363
[TBL] [Abstract][Full Text] [Related]
9. Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis.
Hassan HT; Zander A
Acta Haematol; 1996; 95(3-4):257-62. PubMed ID: 8677752
[TBL] [Abstract][Full Text] [Related]
10. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
[TBL] [Abstract][Full Text] [Related]
11. Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells.
Pigneux A; Mahon FX; Uhalde M; Jeanneteau M; Lacombe F; Milpied N; Reiffers J; Belloc F
Exp Hematol; 2008 Dec; 36(12):1648-59. PubMed ID: 18922616
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
13. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
[TBL] [Abstract][Full Text] [Related]
14. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
[TBL] [Abstract][Full Text] [Related]
16. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Marcucci G; Stock W; Dai G; Klisovic RB; Liu S; Klisovic MI; Blum W; Kefauver C; Sher DA; Green M; Moran M; Maharry K; Novick S; Bloomfield CD; Zwiebel JA; Larson RA; Grever MR; Chan KK; Byrd JC
J Clin Oncol; 2005 May; 23(15):3404-11. PubMed ID: 15824414
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG
Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404
[TBL] [Abstract][Full Text] [Related]
20. Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway.
Bortul R; Tazzari PL; Billi AM; Tabellini G; Mantovani I; Cappellini A; Grafone T; Martinelli G; Conte R; Martelli AM
Br J Haematol; 2005 Jun; 129(5):677-86. PubMed ID: 15916691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
